|Bid||5.42 x 1000|
|Ask||5.43 x 700|
|Day's Range||5.28 - 5.43|
|52 Week Range||1.93 - 5.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.75|
Cerus Corporation announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation announced today that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets. The INTERCEPT Blood System for platelets is intended for the ex vivo treatment and storage of platelet components.
Cerus Corporation announced today that Baylor St. Luke’s Medical Center in Houston became the first center in the continental U.S. to enroll patients in Cerus’ RedeS study.
Longtime Concord company Cerus Corp. signed a lease with Sierra Pacific Properties for a new headquarters office.
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Stock Monitor: Cerus Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 16, 2018 / Active-Investors.com has just released a free research report on Tyme Technologies, Inc. (NASDAQ: TYME ). If you ...
Investors are always looking for growth in small-cap stocks like Cerus Corporation (NASDAQ:CERS), with a market cap of US$664.83M. However, an important fact which most ignore is: how financially healthyRead More...
Cerus Corporation announced today that The Community Blood Center of Appleton, Wisconsin received approval by the U.S. Food and Drug Administration on their Biologics License Application requesting allowance of interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System.
The Concord, California-based company said it had a loss of 10 cents per share. The biomedical products company posted revenue of $16.2 million in the period. For the year, the company reported that its ...
Cerus Corporation today announced financial results for the fourth quarter and year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Cerus Corporation (NASDAQ: CERS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:15 PM Eastern Time. To ...
Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 8:00 am ET on Tuesday, March 13, 2018.
For Cerus Energy Group Ltd’s (TSXV:CEA) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. CEA isRead More...
Cerus Corporation announced today that its fourth quarter and year end results for 2017 will be released on Thursday, March 8, 2018, after the close of the stock market.
NEW YORK, Feb. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REV ...
Cerus Corporation today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares.
Cerus Corporation today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.0 million, before deducting estimated offering expenses payable by Cerus.
Cerus Corporation today announced that it has commenced a registered underwritten public offering of $50.0 million of its common stock. In addition, Cerus has granted the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock.
Cerus Corporation (NASDAQ:CERS) and Pfizer Inc. (NYSE:PFE) are both gaining strength heading into the end of the week in the biotechnology space on the back of a couple of fresh data releases. Here’s what the data from each showed and what it means going forward. Cerus Corporation This one is rooted in a phase III […] The post Cerus, Pfizer Both Just Put Out Key Late Stage Data appeared first on Market Exclusive.
NEW YORK, NY / ACCESSWIRE / January 25, 2018 / Cerus shares skyrocketed to a new high on Wednesday after the company announced positive results from its clinical trial of Intercept. Halozyme Therapeutics ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Comcast Corporation (NASDAQ: CMCSA ) stock lost 0.2 ...